Evidence map›Paper›PMID 32138732›Full record

ArticleJournal of biomedical science2020

LncRNA MALAT1 silencing protects against cerebral ischemia-reperfusion injury through miR-145 to regulate AQP4.

Hongwei Wang, Xiaoxiao Zheng, Jing Jin, Li Zheng, Ting Guan, Yangfan Huo, Shufen Xie, Ying Wu, Wei Chen

Open access · diamondAbstract read
In one paragraph

Article in Journal of biomedical science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 1 pooled it
8.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 1 synthesis or guideline pooled it, 153 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. LncRNAs Orchestrating Neuroinflammation: A Comprehensive Review.Cellular and molecular neurobiology · 2025
    Review
  17. Review
  18. Article
  19. Article
  20. Frontiers in pharmacology · 2025
    Article

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Hongwei WangDepartment of anesthesiology, Tongde hospital of Zhejiang Province, Hangzhou, 310012, Zhejiang, China.
Xiaoxiao ZhengCancer Institute of Integrated traditional Chinese and Western Medicine, Zhejiang Academy of Traditional Chinese Medicine, Tongde hospital of Zhejiang Province, NO.234, Gucui Road, Hangzhou, 310012, Zhejiang, China.
Jing JinDepartment of Neurosurgery, The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, 310003, China.
Li ZhengCancer Institute of Integrated traditional Chinese and Western Medicine, Zhejiang Academy of Traditional Chinese Medicine, Tongde hospital of Zhejiang Province, NO.234, Gucui Road, Hangzhou, 310012, Zhejiang, China.
Ting GuanDepartment of anesthesiology, Tongde hospital of Zhejiang Province, Hangzhou, 310012, Zhejiang, China.
Yangfan HuoDepartment of anesthesiology, Tongde hospital of Zhejiang Province, Hangzhou, 310012, Zhejiang, China.
Shufen XieDepartment of anesthesiology, Tongde hospital of Zhejiang Province, Hangzhou, 310012, Zhejiang, China.
Ying WuCancer Institute of Integrated traditional Chinese and Western Medicine, Zhejiang Academy of Traditional Chinese Medicine, Tongde hospital of Zhejiang Province, NO.234, Gucui Road, Hangzhou, 310012, Zhejiang, China. wuying@sibs.ac.cn.
Wei ChenCancer Institute of Integrated traditional Chinese and Western Medicine, Zhejiang Academy of Traditional Chinese Medicine, Tongde hospital of Zhejiang Province, NO.234, Gucui Road, Hangzhou, 310012, Zhejiang, China. wei_chen@zju.edu.cn.
Tongde Hospital of Zhejiang Province · CNZhejiang University · CN

Funding

Health and Family planning commission of Zhejiang Province 2017KY327Key Research & Development Plan of Zhejiang Province 2019C03034National Natural Science Foundation of China 31900543, 81972674, 81972693Natural Science Foundation of Zhejiang Province LR20H160001the Innovative Talents Training Project of Zhejiang Health Bureau 2018the Scientific Research Project of Health and Family Planning Commission of Zhejiang Province 2016147673Zhejiang Provincial Medical and Health Science and Technology Project WKJ-ZJ-1916Zhejiang Provincial Traditional Chinese Medicine Science and Technology Project 2020ZZ004
6 · The paper itself

Abstract

backgroundThe present study aimed to verify whether long noncoding RNA (lncRNA) MALAT1 is involved in brain tissue damage induced by ischemia-reperfusion injury, and to explore the mechanism by which MALAT1 regulates aquaporin 4 (AQP4).

methodsIn this study, we established glucose deprivation (OGD)/reoxygenation (RX) astrocyte cell model and middle cerebral artery occlusion (MCAO)/reperfusion mouse model in vitro and in vivo. Then cell counting kit-8 assay, flow cytometry analysis, Triphenyltetrazolium chloride (TTC) staining, and western blotting were used to determine cell viability, cell apoptosis, cerebral infarction volume, and the abundance of AQP4, respectively.

resultsWe found that the level of MALAT1 was significantly upregulated in both the MCAO/reperfusion model and OGD/RX model. Knockdown of MALAT1 increased cell viability and reduced cell apoptosis in MA-C cells, while an AQP4 siRNA combined with a siRNA targeting MALAT1 could not enhance this effect. Further experiments showed that MALAT1 positively regulated AQP4 expression via miR-145. The MALAT1 siRNA did not alleviate the exacerbation of damage after miR-145 inhibitor action. However, an miR-145 inhibitor reversed the protection effects of MALAT1, indicating that MALAT1 silencing protects against cerebral ischemia-reperfusion injury through miR-145. TTC staining showed that the infracted area of whole brain was significantly attenuated in treated with sh-MALAT1 group in vivo.

conclusionTaken together, our study confirmed that MALAT1 promotes cerebral ischemia-reperfusion injury by affecting AQP4 expression through competitively binding miR-145, indicating that MALAT1 might be a new therapeutic target for treatment cerebral ischemic stroke.

Indexed as

Gene Expression RegulationGene SilencingAnimalsAquaporin 4MaleMiceMice, Inbred C57BLMicroRNAsReperfusion InjuryRNA, Long NoncodingUp-RegulationAqp4 protein, mouseAquaporin 4Malat1 long non-coding RNA, mouseMicroRNAsMIRN145a microRNA, mouseRNA, Long NoncodingAQP4Cerebral ischemia-reperfusion injuryMALAT1miR-145

Identifiers

PMID32138732
PMCPMC7059719
OpenAlexW3012055672

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.